Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial [0.03%]
纳昔塔马布联合逐步增加剂量的粒细胞-巨噬细胞集落刺激因子治疗原发难治高危神经母细胞瘤I/II期临床试验结果
Brian H Kushner,Shakeel Modak,Audrey Mauguen et al.
Brian H Kushner et al.
Background: With high-risk neuroblastoma, post-induction metastases in bone marrow (BM)/bones confers a poor prognosis but can respond to anti-GD2 antibody, such as naxitamab. We report results of a phase I/II trial. ...
Inflammasomes and pyroptosis in cancer: mechanisms and therapeutic advances [0.03%]
癌症中的炎性小体和细胞焦亡：机制及治疗进展
Wonhyoung Seo,Bokeum Jung,Taylor Roh et al.
Wonhyoung Seo et al.
Inflammasomes are being increasingly recognized for their critical roles in regulating immune cell infiltration, antitumor immunity, and tumorigenesis in cancer biology. The expression and activation of inflammasomes, which vary according t...
Jia Xu,Zhaozhao Chen,Liman Su et al.
Jia Xu et al.
Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a highly efficacious treatment for refractory and relapsed hematological malignancies in recent years. However, the complex manufacturing procedures, stringent logistical requi...
Emerging advances in CAR-T therapy for solid tumors: latest clinical trial updates from 2025 ASCO annual meeting [0.03%]
CAR-T疗法治疗实体瘤的新进展：2025年ASCO年会最新临床试验成果更新
Wenze Li,Defeng Zhao,Miao Chen et al.
Wenze Li et al.
Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated a transformative impact in hematologic malignancies and offers a promising strategy to offer new hope for patients with solid tumors who have failed multiple lines of treatme...
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort [0.03%]
针对IDH1突变的急性髓系白血病患者的ivosidenib治疗：二期关键队列的最终五年结果报告
Jorge Cortes,Antonio Curti,Pierre Fenaux et al.
Jorge Cortes et al.
Background: Olutasidenib is an oral, selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), FDA-approved for relapsed/refractory (R/R) acute myeloid leukemia (AML) based on a registrational, phase 2, open-label...
B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study [0.03%]
靶向B细胞成熟抗原的正电子发射型计算机断层显像/计算机断层成像技术在多发性骨髓瘤中的应用：一项首个人体研究
Tingfei Gu,Zhao Chen,Tianyao Wang et al.
Tingfei Gu et al.
B-cell maturation antigen (BCMA)-targeted positron emission tomography/computed tomography (PET/CT) represents a promising tool for the management of multiple myeloma, enabling noninvasive and quantitative evaluation across different diseas...
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape [0.03%]
靶向B7-H3的纳米抗体嵌合抗原受体T细胞控制多发性骨髓瘤生长，而双特异性BCMA/B7-H3 CAR-T细胞克服了抗原逃逸现象
Arne Van der Vreken,Fien Meeus,Chenggong Tu et al.
Arne Van der Vreken et al.
Background: CAR T cell therapy targeting BCMA has shown remarkable efficacy in multiple myeloma (MM), but relapses occur due to T cell exhaustion and the emergence of BCMA-negative subpopulations. Novel targets are needed...
Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma [0.03%]
BCL11B耗竭诱导的NK细胞定向重编程增强针对胰腺导管腺癌的免疫疗法
Han-Seop Kim,Jae Yun Kim,Ji-Young Lee et al.
Han-Seop Kim et al.
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterized by desmoplastic stroma, immunosuppressive tumor microenvironment (TME), and resistance to standard therapies. Natural killer (NK) ce...
First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies [0.03%]
DT2216（一种选择性BCL-xL降解剂）治疗复发/难治性实体瘤患者的首次人体Ⅰ期临床研究
Daruka Mahadevan,Minal Barve,Devalingam Mahalingam et al.
Daruka Mahadevan et al.
Background: Small molecule inhibition of BCL-XL with navitoclax resulted in on-target dose-limiting thrombocytopenia. DT2216 was more effective than navitoclax and reduced platelet toxicity in preclinical models by select...
MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia [0.03%]
microRNA-142可提高CAR-T细胞在急性髓系白血病中的疗效
Kaito Harada,Dandan Zhao,Miso Park et al.
Kaito Harada et al.
Background: Interleukin-1 receptor accessory protein (IL1RAP) is selectively expressed on both bulk blasts and leukemic stem cells (LSCs) in acute myeloid leukemia (AML), while its expression is virtually absent on normal...